Immunological Follow-up After SARS CoV2 Vaccination in Kidney Transplant Recipients

Launched by UNIVERSITY HOSPITAL, STRASBOURG, FRANCE · Feb 16, 2021

Keywords

ClinConnect Summary

This clinical trial is studying how well kidney transplant patients respond to the SARS-CoV-2 vaccine. Researchers want to find out if these patients develop protective antibodies and immune responses after getting vaccinated. The trial includes kidney transplant patients who have had their transplant for more than three months and are receiving the vaccine as part of their regular medical care.

To join the study, participants need to be at least 18 years old, have received the vaccine, and not have any serious allergies or health issues that would prevent them from getting the shot. During the trial, participants will have their blood tested to see how their bodies are responding to the vaccine. This research is important because it will help understand how effective the vaccine is for people who have had a kidney transplant, ensuring they get the best protection possible.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female, 18 years of age or older
• • Patient vaccinated against SARS-CoV-2 as part of routine care
• • Kidney or pancreatic kidney transplant
• • Transplantation for more than 3 months
• • Subject affiliated to a social protection health insurance
• • Subject able to understand the objectives and risks of the research and to give signed and dated informed consent
• Exclusion Criteria:
• • History of anaphylactic shock or known allergy to PEG
• • Known history of COVID or positive Covid serology in the 3 months prior to vaccination
• • Contraindication to an intramuscular injection
• • Impossibility to give informed information about the subject (subject in an emergency situation, difficulties in understanding the subject, ...)
• • Subject under safeguard of justice
• • Subject under guardianship